var title_f5_3_5168="Divertic with fecolith Endosc";
var content_f5_3_5168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulum with nonobstructing fecolith",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nonobstructing fecolith within a large diverticulum could predispose to the development of diverticulitis if the fecolith were to obstruct the diverticulum, thereby increasing diverticular pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5168=[""].join("\n");
var outline_f5_3_5168=null;
var title_f5_3_5169="Gelatin, pectin, and methylcellulose: Drug information";
var content_f5_3_5169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gelatin, pectin, and methylcellulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral irritation: Topical: Press small dabs into place until the involved area is coated with a thin film; do not try to spread onto area; may be used as often as needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F175608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4423967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief from minor oral irritations",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8948 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5169=[""].join("\n");
var outline_f5_3_5169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175609\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175606\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175608\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175607\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4423967\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175603\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_3_5170="Hyperechoic nodule";
var content_f5_3_5170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperechoic nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of the thyroid region that shows a hyperechoic nodule (N) in the right lobe of a goiter. The tracheal cartilage (TC) is seen, as is the isthmus above that. A 14.0 MHz transducer was used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5170=[""].join("\n");
var outline_f5_3_5170=null;
var title_f5_3_5171="Popliteal nerve block ultrasound";
var content_f5_3_5171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Popliteal nerve block ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With ultrasound, a popliteal block can be performed from a posterior or lateral approach. The posterior approach places the patient in a prone position. The probe is placed transversely over the calf muscle and the tibial and common fibular nerves identified. Moving the transducer cephalad will identify the point where these nerves have divided from the sciatic nerve. The sciatic nerve is blocked proximal to this point to ensure that the leg is completely anesthetized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5171=[""].join("\n");
var outline_f5_3_5171=null;
var title_f5_3_5172="Nitazoxanide: Patient drug information";
var content_f5_3_5172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nitazoxanide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     see \"Nitazoxanide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/43/44723?source=see_link\">",
"     see \"Nitazoxanide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alinia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nitazoxanide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 1 week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11403 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5172=[""].join("\n");
var outline_f5_3_5172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018230\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018229\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018234\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018235\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018237\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018232\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018233\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018238\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018239\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=related_link\">",
"      Nitazoxanide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/43/44723?source=related_link\">",
"      Nitazoxanide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_3_5173="Hypospadias 2 stage repair 1";
var content_f5_3_5173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Stage one of two-stage hypospadias repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 660px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first stage includes correction of penile curvature and transfer of dorsal foreskin to the ventral aspect of the penis. A) Scrotal hypospadias with penile curvature. B) Initial dissection removing ventral tethering urethral plate tissue. C) Penile straightening with dorsal plication. D) Confirmation of a straight penis with artificial saline erection. E) In select cases, part of urethral plate can be preserved. F) The dorsal skin is split and wrapped to the ventrum. G) First stage complete with temporary catheter in the urethral meatus at the penile scrotal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure modified from TTMed (Timely Topics in Medicine)-Urology USA. Copyright &copy; 2009 Prous Science S.A.U. or its licensors. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5173=[""].join("\n");
var outline_f5_3_5173=null;
var title_f5_3_5174="Enterobiasis life cycle";
var content_f5_3_5174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Enterobiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eggs are deposited on perianal folds",
"    <strong>",
"     (1)",
"    </strong>",
"    . Self-infection occurs by transferring infective eggs to the mouth with hands that have scratched the perianal area",
"    <strong>",
"     (2)",
"    </strong>",
"    . Person-to-person transmission can also occur through handling of contaminated clothes or bed linens. Enterobiasis may also be acquired through surfaces in the environment that are contaminated with pinworm eggs (eg, curtains, carpeting). Some small number of eggs may become airborne and inhaled. These would be swallowed and follow the same development as ingested eggs. Following ingestion of infective eggs, the larvae hatch in the small intestine",
"    <strong>",
"     (3)",
"    </strong>",
"    and the adults establish themselves in the colon",
"    <strong>",
"     (4)",
"    </strong>",
"    . The time interval from ingestion of infective eggs to oviposition by the adult females is about one month. The life span of the adults is about two months. Gravid females migrate nocturnally outside the anus and oviposit while crawling on the skin of the perianal area",
"    <strong>",
"     (5)",
"    </strong>",
"    . The larvae contained inside the eggs develop (the eggs become infective) in four to six hours under optimal conditions",
"    <strong>",
"     (1)",
"    </strong>",
"    . Retroinfection, or the migration of newly hatched larvae from the anal skin back into the rectum, may occur but the frequency with which this happens is unknown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Enterobiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5174=[""].join("\n");
var outline_f5_3_5174=null;
var title_f5_3_5175="Coal workers pneumoconiosis PA";
var content_f5_3_5175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coal worker's pneumoconiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple noncalcified micronodules throughout both lungs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5175=[""].join("\n");
var outline_f5_3_5175=null;
var title_f5_3_5176="Dronedarone: Drug information";
var content_f5_3_5176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dronedarone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9733?source=see_link\">",
"    see \"Dronedarone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7900885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7891987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Multaq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9477224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Multaq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7900889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7901012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Atrial fibrillation/atrial flutter:",
"     </b>",
"     Oral: 400 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7901013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7901014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7901015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7901021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multaq&reg;: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7900887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8103987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM171764.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM171764.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7901017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with morning and evening meal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7900890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13657555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative antiarrhythmic for the treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy (HCM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13934349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate/high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7900963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     (Bazett) prolongation (28% [placebo: 19%]; defined as &gt;450 msec in males or &gt;470 msec in females)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased &ge;10% (51%; occurred 5 days after initiation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Allergic dermatitis (&le;5%), dermatitis (&le;5%), eczema (&le;5%), pruritus (&le;5%), rash (&le;5%; described as generalized, macular, maculopapular, erythematous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (9%), nausea (5%), abdominal pain (4%), dyspepsia (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal taste, acute hepatic failure (requiring transplant), anaphylactic reactions, angioedema, heart failure (new or worsened), hepatic function tests increased, hepatic injury, hyperbilirubinemia, interstitial lung disease, leukocytoclastic vasculitis, photosensitivity reaction, pneumonitis, pulmonary fibrosis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7900896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dronedarone or any component of the formulation; permanent atrial fibrillation (patients in whom sinus rhythm will not or cannot be restored); symptomatic heart  failure (HF with recent decompensation requiring hospitalization or NYHA Class IV symptoms; second- or third-degree heart block or sick sinus syndrome (except in patients with a functioning artificial pacemaker); bradycardia &lt;50 bpm; concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, or ritonavir); concomitant use of drugs or herbal products known to prolong the QT interval increasing the risk for torsade de pointes (eg, phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, or class I and III antiarrhythmics); QT",
"     <sub>",
"      c",
"     </sub>",
"     (Bazett) interval &ge;500 msec or PR interval &gt;280 msec; liver or lung toxicity related to previous amiodarone use; severe hepatic impairment; pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to dronedarone or any component of the formulation; permanent atrial fibrillation of any duration where sinus rhythm cannot be restored and further attempts to restore it are no longer considered; history of or current heart failure regardless of NYHA class; left ventricular systolic dysfunction; sinus node dysfunction; atrial conduction defects;  complete or distal bundle branch block, unstable hemodynamic conditions; pulmonary toxicity related to prior amiodarone use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7900897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): New-onset or worsening HF symptoms have been observed in postmarketing use. If patient  develops new or worsening HF symptoms (eg, weight gain, dependent edema, or increasing shortness of breath) requiring hospitalization while on therapy, discontinue dronedarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Severe liver injury, including acute liver failure leading to liver transplant, has been rarely reported. If liver injury is suspected, discontinue therapy and evaluate liver enzymes/bilirubin. Appropriate treatment should be started and therapy should not be reinitiated if liver injury is confirmed. Advise patients to report any signs or symptoms of hepatic injury (unusual fatigue, jaundice, nausea, vomiting, abdominal pain, and/or fever). Consider periodic monitoring of serum liver enzymes and bilirubin, especially during the first 6 months of therapy. Use is contraindicated in patients with previous hepatotoxicity with amiodarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation: Dronedarone induces a moderate prolongation of the QT interval (average ~10 msec); much greater effects have been observed. Use in patients with QT",
"     <sub>",
"      c",
"     </sub>",
"     (Bazett) interval &ge;500 msec is contraindicated; discontinue use of dronedarone if this occurs during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory effects: Interstitial lung disease (including pulmonary fibrosis and pneumonitis) has been reported with use.  Evaluate patients with onset of dyspnea or nonproductive cough for pulmonary toxicity. Discontinue therapy with confirmed pulmonary toxicity. Use is contraindicated in patients with previous pulmonary toxicity with amiodarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serum creatinine elevation: Dronedarone may produce a slight increase in serum creatinine (~0.1 mg/dL) within 7 days of initiation due to inhibition of tubular secretion; glomerular filtration rate is not affected. Effect is reversible upon discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac devices (eg, implanted defibrillators, pacemakers): Chronic administration of antiarrhythmic drugs may affect defibrillation or pacing thresholds. Assess when initiating dronedarone and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF):",
"     <b>",
"      [U.S. Boxed Warning]: The risk of death is doubled when used in patients with symptomatic HF with recent decompensation requiring hospitalization or  NYHA Class IV symptoms; use is contraindicated in these patients.",
"     </b>",
"     Canadian labeling contraindicates use of dronedarone in patients with a history of or current heart failure, regardless of NYHA class.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; use is contraindicated in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Permanent atrial fibrillation (AF):",
"     <b>",
"      [U.S. Boxed Warning]: Use in patients with permanent atrial fibrillation doubles the risk of death, stroke, and hospitalization for heart failure. Use is contraindicated in patients with AF who will not or can not be converted to normal sinus rhythm.",
"     </b>",
"     Monitor ECG at least every 3 months. Cardiovert patients who are in AF (if clinically indicated) or discontinue dronedarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antithrombotic therapy: Initiate appropriate antithrombotic therapy prior to starting dronedarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs metabolized by CYP enzymes: Dronedarone is a moderate inhibitor of CYP3A4 and CYP2D6 enzymes and has potential to inhibit p-glycoprotein, which may lead to increased serum concentrations/toxicity of a number of medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Use caution when initiating dronedarone in patients on warfarin. Cases of increased INR with or without bleeding have occurred in patients treated with warfarin; monitor INR closely after initiating dronedarone in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients. Avoid use in patients with permanent atrial fibrillation or heart failure (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women of childbearing potential: Should use effective contraceptive methods during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7907323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Dronedarone may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Dronedarone may enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.  Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone. Management: Use lower starting doses of the nondihydropyridine calcium channel blockers (i.e., verapamil, diltiazem), and only consider increasing calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Dronedarone may increase the serum concentration of Dabigatran Etexilate.  Management: Increase monitoring for bleeding; dabigatran etexilate dose reduction may be necessary in moderate renal dysfunction; avoid this combination in severe renal dysfunction. Canadian labeling recommends avoiding this combination regardless of renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid concurrent use of digoxin when possible.  If concurrent use is necessary, reduce adult digoxin dose by 50%,  monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Dronedarone may increase the serum concentration of DOCEtaxel.  Management: Avoid this combination whenever possible.  If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Dronedarone may increase the serum concentration of Lovastatin.  Management: Limit lovastatin to a maximum of 20 mg/day (in adults).  Increase monitoring for signs of lovastatin toxicity (e.g., myopathy, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: Dronedarone may increase the serum concentration of Red Yeast Rice. In particular, concentrations of the lovastatin-like components may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Dronedarone may increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Dronedarone may increase the serum concentration of Simvastatin.  Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Dronedarone may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7900971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food increases the rate and extent of absorption of dronedarone; bioavailability is increased 11% with a high-fat meal. Grapefruit juice increases bioavailability of dronedarone threefold; altered effects are possible. Management: Take with food. Grapefruit/grapefruit juice should be avoided during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease dronedarone levels; ephedra may worsen arrhythmia. Management: Avoid St John&rsquo;s wort, ephedra, and dong quai.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7900891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7900892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies. May cause fetal harm when administered to a pregnant woman, use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7900894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7900895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether dronedarone is secreted in human milk. Because the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7901016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a meal. Grapefruit juice is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Multaq Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $575.24",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7901019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG (at least every 3 months), blood pressure, heart rate and rhythm throughout therapy; assess patient for signs of lethargy, edema of the hands or feet; monitor serum electrolytes, especially potassium and magnesium; serum liver enzymes and bilirubin (periodically, especially during the first 6 months of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Patients with implantable cardiac devices: Monitor pacing or defibrillation thresholds with initiation of dronedarone and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional monitoring recommendations: ECG at least every 6 months during therapy; serum creatinine 1 week after initiating therapy followed by periodic renal function tests;  periodic pulmonary function assessment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Multaq (AT, AU, CH, CO, CZ, DE, DK, EE, FR, GB, HK, HN, IE, IL, KP, MY, NL, NO, PE, PH, PL, PT, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7900974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A noniodinated antiarrhythmic agent structurally related to amiodarone exhibiting properties of all 4 antiarrhythmic classes. Dronedarone inhibits sodium (I",
"     <sub>",
"      Na",
"     </sub>",
"     ) and potassium (I",
"     <sub>",
"      kr",
"     </sub>",
"     , I",
"     <sub>",
"      kS",
"     </sub>",
"     , I",
"     <sub>",
"      k1",
"     </sub>",
"     , and I",
"     <sub>",
"      k-ACh",
"     </sub>",
"     ) channels resulting in prolongation of the action potential and refractory period in myocardial tissue without reverse-use dependent effects; decreases AV conduction and sinus node function through inhibition of calcium (I",
"     <sub>",
"      Ca-L",
"     </sub>",
"     ) channels and beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptor blocking activity. Similar to amiodarone, dronedarone also inhibits alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptor mediated increases in blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7900976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20 L/kg (based on a 70 kg patient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4 to active N-debutyl metabolite  (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     as potent as dronedarone) and other inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: Without food: 4%; With high-fat meal: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 13-19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (84% mainly as metabolites); urine (~6% mainly as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Connolly SJ, Camm AJ, Halperin JL, et al, &ldquo;Dronedarone in High Risk Permanent Atrial Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(24):2268-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/22082198/pubmed\" id=\"22082198\" target=\"_blank\">",
"        22082198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hohnloser SH, Crijns HJ, van Eickels M, et al, &ldquo;Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(7):668-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/19213680/pubmed\" id=\"19213680\" target=\"_blank\">",
"        19213680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&oslash;ber L, Torp-Pedersen C, McMurray JJV, et al, &ldquo;Increased Mortality After Dronedarone Therapy for Severe Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(25):2678-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/18565860/pubmed\" id=\"18565860\" target=\"_blank\">",
"        18565860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanofi-Aventis, Multaq (Dronedarone) Briefing Document for the Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division of the U.S. Food and Drug Administration, March 18, 2009. Available at",
"      <a href=\"file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM134981.pdf\" target=\"_blank\">",
"       file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM134981.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh BN, Connolly SJ, Crijns HJ, et al, &ldquo;Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(10):987-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/17804843/pubmed\" id=\"17804843\" target=\"_blank\">",
"        17804843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tschuppert Y, Buclin T, Rothuizen LE, et al, &ldquo;Effect of Dronedarone on Renal Function in Healthy Subjects,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(6):785-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/17662087/pubmed\" id=\"17662087\" target=\"_blank\">",
"        17662087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wegener FT, Ehrlich JR, and Hohnloser SH, &ldquo;Dronedarone: An Emerging Agent With Rhythm- and Rate-Controlling Effects,&rdquo;",
"      <i>",
"       J Cardiovasc Electrolphysiol",
"      </i>",
"      , 2006, 17(Suppl 2):17-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/3/5176/abstract-text/16939434/pubmed\" id=\"16939434\" target=\"_blank\">",
"        16939434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9037 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5176=[""].join("\n");
var outline_f5_3_5176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900885\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7891987\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9477224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900889\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901012\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901013\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901014\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901015\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901021\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900887\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103987\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901017\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900890\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657555\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934349\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900963\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900896\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900897\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837936\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7907323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900971\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900891\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900892\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900894\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900895\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901016\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322460\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901019\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962005\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900974\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900976\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9733?source=related_link\">",
"      Dronedarone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_3_5177="Wound healing and risk factors for non-healing";
var content_f5_3_5177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wound healing and risk factors for non-healing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     David G. Armstrong, DPM, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Andrew J Meyr, DPM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5177/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/3/5177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1070222483\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wound is a disruption of the normal structure and function of the skin and underlying soft tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute wounds in normal, healthy individuals heal through an orderly sequence of physiological events that include hemostasis, inflammation, epithelialization, fibroplasia, and maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/2\">",
"     2",
"    </a>",
"    ]. When this process is altered or stalled, a chronic wound may develop and is more likely to occur in patients with underlying disorders such as peripheral artery disease, diabetes, venous insufficiency, nutritional deficiencies, and other disease states. Chronic ulceration commonly affects the lower extremities with a prevalence that ranges between 0.18 and 1.3 percent in the adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wounding mechanisms, the normal phases of wound healing and alterations in wound healing due to disease will be reviewed here. The clinical evaluation and topical management of open wounds is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=see_link\">",
"     \"Clinical assessment of wounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222490\">",
"    <span class=\"h1\">",
"     WOUND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds are generally classified as acute or chronic. Although there is no specific time frame determining the difference between an acute or chronic wound, chronic wounds are generally associated with physiological impairments that slow or prevent wound healing. Wounds may be caused by a variety of mechanisms including acute injury to the skin (abrasion, puncture, crush), surgery and other etiologies that cause initially intact skin to break down (eg, ischemia, pressure).",
"   </p>",
"   <p>",
"    Acute wounds have an easily identifiable mechanism of injury with skin integrity disrupted typically due to some form of trauma. Traumatic skin disruption can result from blunt or penetrating mechanisms (gunshot, animal bite) and an array of wound sizes, depths, and locations can result. Simple or complicated lacerations, abrasions, burns and significant tissue defects can occur, each requiring individualized management and care.",
"   </p>",
"   <p>",
"    Patients with impairment in the sensation of pain are vulnerable to acute and chronic repetitive injuries. In some patients with sensory neuropathy, the injury may go unnoticed if the injured area is not routinely inspected. Patients with diabetes, particularly those with arterial obstruction, are at high risk. (See",
"    <a class=\"local\" href=\"#H55266174\">",
"     'Diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgical wounds are a controlled form of trauma created in the operating room environment. Surgical wounds are classified according to the degree of bacterial load or contamination of the surgical wound. The categories, clean, clean-contaminated, contaminated, and dirty are used to predict the risk of surgical wound infection which can impact wound healing. The majority of clean and clean-contaminated wounds are closed primarily at the completion of the surgery. Contaminated and dirty wounds (eg, fecal contamination, debridement for wound infection) are typically packed open.",
"   </p>",
"   <p>",
"    Any mechanism that decreases blood flow in the skin for a prolonged period of time has the potential to cause ischemic breakdown of the skin. Skin perfusion may be impaired due to proximal arterial obstruction (eg, peripheral artery disease), vascular compression (eg, hematoma, immobility causing focal pressure), or microvascular occlusion or thrombosis (eg, vasculitis, cholesterol crystals). (See",
"    <a class=\"local\" href=\"#H1070222581\">",
"     'Risk factors for non-healing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222546\">",
"    <span class=\"h1\">",
"     PHASES OF WOUND HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound healing occurs as a cellular response to tissue injury and involves activation of keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets (",
"    <a class=\"graphic graphic_figure graphicRef58665 \" href=\"UTD.htm?22/60/23498\">",
"     figure 1",
"    </a>",
"    ). The process involves organized cell migration and recruitment of endothelial cells for angiogenesis. Many growth factors and cytokines released by these cell types coordinate and maintain wound healing. Once hemostasis is achieved, acute wounds normally heal in an orderly and efficient manner characterized by overlapping phases that include inflammation, epithelialization, fibroplasia, and maturation (",
"    <a class=\"graphic graphic_algorithm graphicRef70581 \" href=\"UTD.htm?35/3/35894\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute wounds transition through the stages of wound healing as a linear pathway, with clear start- and endpoints (",
"    <a class=\"graphic graphic_figure graphicRef72355 \" href=\"UTD.htm?17/39/18046\">",
"     figure 2",
"    </a>",
"    ). Chronic wounds are arrested in one of these stages, usually the inflammatory stage, and cannot progress further. In these situations, the normal physiology of the linear pathway is transformed into the pathophysiology of a chronic cycle, without a clear wound closure endpoint.",
"   </p>",
"   <p>",
"    Restoration of skin integrity following acute surgical wounding in normal individuals is usually complete within two to four weeks. However, following initial successful surgical skin closure, open wounds may result from disruption of the sutured skin, which can be due to technical error, infection or the presence of foreign material within the wound. Healing of a surgical wound can be delayed or prolonged in patients with disease states that impair the healing process. (See",
"    <a class=\"local\" href=\"#H1070222581\">",
"     'Risk factors for non-healing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The quality of the healed tissue depends upon the severity of tissue trauma, the suture material used in repair, and the presence of factors that may delay healing or reduce the tensile strength of the final scar. In animal models, un-sutured fascial wounds have minimal strength in the first week of healing, achieve 30 to 50 percent of unwounded tissue strength after four to six weeks, 60 percent at six months, and slowly continue to get stronger, but may never achieve 100 percent of their previous strength [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55260958\">",
"    <span class=\"h2\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after injury to the skin, small vessels within the wound constrict to provide at least a measure of hemostasis for 5 to 10 minutes. Platelets aggregate in severed vessels and trigger the clotting cascade and release essential growth factors and cytokines that are important for the initiation and progression of wound healing (eg, platelet-derived growth factor, transforming growth factor-&beta;) (",
"    <a class=\"graphic graphic_figure graphicRef77972 \" href=\"UTD.htm?28/9/28826\">",
"     figure 3",
"    </a>",
"    ). The fibrin matrix that results stabilizes the wound and provides a provisional scaffold for the wound healing process. Hemostasis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Larger vessels may require pressure, hemostatic agents or electrocautery to achieve hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=see_link\">",
"     \"Overview of topical hemostatic agents used in the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222553\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory phase of healing is sometimes called the lag phase because wound strength does not begin to return immediately. The inflammatory phase is completed within three days, except in the presence of infection or other causes of wound chronicity.",
"   </p>",
"   <p>",
"    Key components of this phase are increased vascular permeability, and cellular recruitment. Multiple events contribute to these processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mononuclear leukocytes accumulate and are transformed into macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/6\">",
"       6",
"      </a>",
"      ]. The maturation of blood-derived monocytes into macrophages is heralded by several events, including secretion of vimentin, which is a structural filament protein involved in wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mast cells degranulate, releasing histamine and other mediators of vasodilation and cellular migration.",
"     </li>",
"     <li>",
"      Release of vasoactive substances from stromal mast cells makes small vessels permeable to molecular and cellular mediators of the inflammatory response. The resulting accumulation of plasma and cellular elements is noted clinically as edema, or swelling.",
"     </li>",
"     <li>",
"      Chemotaxis results in migration and concentration of polymorphonuclear leukocytes that digest bacteria, foreign debris, and necrotic tissue with lysosomal enzymes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The healing progression of chronic wounds usually becomes arrested in this inflammatory stage. The presence of necrotic tissue, foreign material and bacteria result in the abnormal production of metalloproteases which alter the balance of inflammation and impair the function of the cytokines described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222560\">",
"    <span class=\"h2\">",
"     Epithelialization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelialization (also called migration) refers to basal cell proliferation and epithelial migration occurring in the fibrin bridgework inside a clot (",
"    <a class=\"graphic graphic_picture graphicRef68364 \" href=\"UTD.htm?31/37/32341\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/8\">",
"     8",
"    </a>",
"    ]. Proliferation continues until individual cells are surrounded by cells of similar type. In a clean surgical wound, the epithelial cells migrate downward to meet deep in the dermis (",
"    <a class=\"graphic graphic_picture graphicRef52383 \" href=\"UTD.htm?3/29/3542\">",
"     picture 2",
"    </a>",
"    ). Migration ceases when the layer is rejuvenated; this is normally completed within 48 hours of surgery. The superficial layer of epithelium creates a barrier to bacteria and other foreign bodies. However, it is very thin, easily traumatized, and gives little tensile strength.",
"   </p>",
"   <p>",
"    The process of epithelialization is challenged by wounds that are not primarily closed, but instead are expected to heal by secondary intention. In these wounds, the physical distance of epithelial migration is increased across the length and width and depth of the wound.",
"   </p>",
"   <p>",
"    This process may be further impaired by the presence of biofilm and senescent cells on the wound edge or base. Biofilm is an extracellular matrix produced by bacteria that irreversibly binds to the wound base, promoting inflammation and impairing epithelialization. Epithelial cells at the wound edge may also become senescent, or mitotically inactive and unable to perform the DNA replication necessary for the process of proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222567\">",
"    <span class=\"h2\">",
"     Fibroplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroplasia consists of fibroblast proliferation, accumulation of ground substance, and collagen production. Fibroblasts are transformed from local mesenchymal cells, are usually present in the wound within 24 hours, and predominate by the tenth postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/10\">",
"     10",
"    </a>",
"    ]. They attach to the fibrin matrix of the clot, multiply, and produce glycoprotein and mucopolysaccharides, which make up ground substance.",
"   </p>",
"   <p>",
"    In addition, fibroblasts produce contractile proteins. These contractile cells, which are designated myofibroblasts, are present in the wound by the fifth day and have characteristics of smooth muscle cells with the ability to contract (",
"    <a class=\"graphic graphic_picture graphicRef69864 \" href=\"UTD.htm?19/27/19895\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60301 \" href=\"UTD.htm?24/45/25304\">",
"     picture 4",
"    </a>",
"    ). Pulling the edges of the wound together is dependent upon tissue mobility. Myofibroblastic cells are lost via apoptosis as repair resolves to form scar.",
"   </p>",
"   <p>",
"    In pathological fibrosis, myofibroblasts persist and are responsible for fibrosis via increased matrix synthesis and for contraction. The exuberant scarring may impede normal organ function or, in the case of skin, result in keloid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=see_link\">",
"     \"Keloids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibroblasts also synthesize collagen, the primary structural protein of the body. Collagen production begins on the second postoperative day, when it is secreted as an amorphous gel devoid of strength. Maximum collagen production does not begin until day five and continues for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/12\">",
"     12",
"    </a>",
"    ]. The developing collagen matrix stimulates angiogenesis. Granulation tissue is the result of the combined production of collagen and growth of capillaries (",
"    <a class=\"graphic graphic_figure graphicRef53136 \" href=\"UTD.htm?15/63/16378\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222574\">",
"    <span class=\"h2\">",
"     Maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key elements of maturation include collagen cross-linking, collagen remodeling, wound contraction and repigmentation (",
"    <a class=\"graphic graphic_picture graphicRef77112 \" href=\"UTD.htm?17/1/17430\">",
"     picture 5",
"    </a>",
"    ). Initially, a triple helix (tropocollagen) is formed by three protein chains; two are identical alpha-1 protein chains and the third is an alpha-2 protein. Bundles of tropocollagen combine to form collagen.",
"   </p>",
"   <p>",
"    Five types of collagen have been identified; types I and III predominate in the skin and aponeurotic layers. The tensile strength of the wound is directly proportional to the amount of collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/13\">",
"     13",
"    </a>",
"    ]. As disorganized collagen is degraded and reformed, covalent cross-links are formed that enhance tensile strength (",
"    <a class=\"graphic graphic_figure graphicRef53467 \" href=\"UTD.htm?36/28/37320\">",
"     figure 5",
"    </a>",
"    ). Maximum strength depends upon the interconnection of collagen subunits. Approximately 80 percent of the original strength of the tissue is obtained by six weeks after surgery (",
"    <a class=\"graphic graphic_figure graphicRef69924 \" href=\"UTD.htm?26/7/26751\">",
"     figure 6",
"    </a>",
"    ), but the diameter and morphology of collagen fibers do not have the appearance of normal skin until 180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rest and immobility are important during the immediate postoperative period for successful healing to occur. However, some physical activity is essential during the maturation phase because light tension increases tensile strength by remodeling, which may continue for many years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55264869\">",
"    <span class=\"h1\">",
"     IMPAIRED WOUND HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is usually not a single primary factor that contributes to impaired wound healing; in fact, the overlapping intricacy of the pathway serves to prevent this from happening. Instead there are multiple, smaller contributing issues that can disrupt the process. As examples, local tissue ischemia and neuropathy can impair chemotaxis during the hemostasis and inflammatory stages. Tissue necrosis and infection alter the balance of inflammation and compete for oxygen. Uncontrolled periwound edema and wound instability disrupt myofibroblast activity, and collagen deposition and cross-linking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070222581\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR NON-HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic wounds affect a substantial proportion of the population and contribute to a significant burden in the hospital setting. Certain patients are at risk for development of a non-healing wound such as those with impaired arterial or venous circulation, immunocompromised states, the elderly, those with diabetes, and any patient with neuropathy or spinal cord injury. The most common nonhealing wounds affecting the lower extremities are associated with peripheral artery disease, diabetes and chronic venous insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/1,2,15,16\">",
"     1,2,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266167\">",
"    <span class=\"h2\">",
"     Peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe peripheral artery disease (PAD) with multilevel arterial obstruction decreases arterial blood flow and diminishes the delivery of oxygen and nutrients to the tissues, and impairs removal of metabolic waste products. Critical limb ischemia develops when blood flow does not meet the metabolic demands of tissue at rest, and manifests clinically with extremity pain, non-healing wounds or tissue loss [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=see_link\">",
"     \"Overview of upper extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Ischemic rest pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266174\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes is a particularly important risk factor for the development of chronic wounds because it is associated with vasculopathy, neuropathy and immunopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes is frequently associated with severe peripheral artery disease with atherosclerosis developing at a younger age and affecting more distal arteries (eg, popliteal, tibial arteries). Peripheral artery disease in combination with diabetic neuropathy contributes to higher rates of non-healing ulcers and limb loss in diabetic patients compared with nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/18\">",
"     18",
"    </a>",
"    ]. Approximately 15 percent of patients with diabetes in the United States will develop a foot ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Peripheral artery obstruction is present in about 20 percent of these patients, and diabetic neuropathy in about 50 percent with about 30 percent having both [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropathy alone can be responsible for the development of diabetic foot ulcers. Neuropathy associated with diabetes affects sensory, motor, and autonomic nerves. Sensory neuropathy diminishes the perception of pain that is protective when tissue injury has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with diabetes may not be aware of the injury, particularly if the injured region cannot be seen or if the patient has a visual impairment. The motor nerves to the intrinsic muscles of the foot are affected in approximately 50 percent of patients with diabetes resulting in claw deformities that transfer pressure to the plantar metatarsal heads. Increased local tissue pressure on the plantar surface or in other regions where bony deformities contact the shoe may lead to skin erosion and ulceration that may go unnoticed in patients with sensory deficits. In addition, autonomic neuropathy causes the skin to become dry and susceptible to skin fissures, tearing and infection due to a loss of sweat and oil gland function. Loss of vascular tone may lead to foot edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of the diabetic foot\", section on 'Screening tests for peripheral neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over 100 known cytologic factors contribute to impaired wound healing in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/23\">",
"     23",
"    </a>",
"    ]. These include decreased or impaired growth factor production, angiogenic response, macrophage function, collagen accumulation, epidermal barrier function, quantity of granulation tissue, keratinocyte and fibroblast migration and proliferation, number of epidermal nerves, bone healing, and abnormal balance between the accumulation of extracellular matrix components and their remodeling by matrix metalloproteinases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266181\">",
"    <span class=\"h2\">",
"     Chronic venous insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous leg ulcers account for about 40 percent of wounds of the lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/23\">",
"     23",
"    </a>",
"    ]. An understanding of the normal anatomy and physiology of the venous return to the heart is essential for understanding the defects present in patients with chronic venous disease and ulceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Faulty vein valves, venous obstruction or failure of the &ldquo;venous pump&rdquo; lead to abnormally directed flow from the deep to superficial venous systems via the perforating veins. The most common site of incompetent perforators is 5 to 10 cm above the medial malleolus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/19\">",
"     19",
"    </a>",
"    ]. Congestion and pooling of blood in the superficial veins leads to venous hypertension, which if sustained, is associated with histologic changes in the capillary system, known as venous hypertensive microangiopathy. These changes include elongation and dilation of the capillary bed, increased surface area of the endothelium, increased amounts of type IV collagen in the basement membrane, and formation of a pericapillary fibrin cuff [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. The combination of abnormal capillaries and high venous pressure produces vessels that are abnormally permeable, leading to the accumulation of water, large proteins (including fibrinogen), and extravasated red blood cells into the interstitial space [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. The &ldquo;white cell trap theory&rdquo; postulates that the macromolecules are thought to trap growth factors and matrix material making them unavailable for tissue repair and the perivascular fibrin cuff may decrease the delivery of oxygen and nutrients leading to skin hypoxia and cell death resulting in the venous ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology of chronic venous disease\", section on 'Histologic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122623182\">",
"    <span class=\"h2\">",
"     Aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin is not excluded from the complex processes of aging. The supply of cutaneous nerves and blood vessels decreases with age, and a general thinning of tissue including dermis and basement membrane. There is a loss of collagen and ability to produce more collagen. These physiologic changes associated with aging contribute to slowed or impaired wound healing in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266188\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease represents another form of local tissue ischemia at the specific location of the wound. It is also obstructive in nature, similar to chronic peripheral artery disease, but is caused by dysmorphic red blood cells physically occluding small vessels, usually of the lower extremities. The location and appearance of sickle cell wounds may be similar to ischemic and venous ulcerations. A peripheral blood smear may be helpful in making the diagnosis. Treatment of these wounds is similar to the treatment of other chronic wounds, but sickle cell wounds are known to progress much slower through wound healing and carry an increased risk of reoccurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Leg ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266195\">",
"    <span class=\"h2\">",
"     Cancer therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55270692\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of chemotherapy may have a detrimental effect on wound healing, specifically through its effects on vascular endothelial growth factor (VEGF). VEGF is an important factor contributing to angiogenesis during the early stages of wound healing, but may also be an important regulator in malignancy, and thus, is a target of cancer therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to these effects, any patient on immunosuppressive therapy is at an increased risk for the development of chronic wounds and wound infection. The inflammatory phase of wound healing may be blunted in patients on long-term immune suppression such as transplant patients, HIV patients and patient on glucocorticoid therapy (eg, rheumatoid arthritis, lupus, Crohn&rsquo;s disease). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55270700\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy has evolved as a powerful tool for tumor control as a sole therapy or administered perioperatively. More than 50 percent of cancer patients receive some form of radiation treatment and, despite improvements in radiation technique, radiation-induced injury still contributes to poor wound healing. The term &ldquo;radiation injury&rdquo; refers to the morphologic and functional changes that can occur in noncancerous tissue as a direct result of ionizing radiation and may include apoptosis (cell death) with low doses of radiation, or outright tissue necrosis with higher doses of radiation. Irradiated skin in the chronic stage is thin, hypovascular, extremely painful, and easily injured by slight trauma or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link&amp;anchor=H22#H22\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Cutaneous syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin ulcers due to radiation injury are more commonly delayed in presentation and are due to ischemic tissue changes. Characteristic features of delayed radiation injury include telangiectasia and eccentric myointimal proliferation in the small arteries and arterioles. The proliferative changes may progress to obstruction or the lumen may thrombose. These ulcers heal very slowly and may persist for several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266202\">",
"    <span class=\"h2\">",
"     Spinal cord disease and immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing periods of prolonged immobilization, particularly those with spinal cord disease, are at an increased risk for the development of chronic wounds. These are typically pressure wounds, similar in pathogenesis and appearance to neuropathic wounds occurring in areas of bony prominence such as the sacrum, knees, ankle malleoli and heels. The sacrum may be particularly at risk when the presence of incontinence in spinal cord patients leads to a moist environment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immobilization in the absence of pressure is probably not a risk factor for wound development or chronicity. In fact, complete immobilization with total contact casting is as an effective treatment for plantar diabetic foot ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266216\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is insufficient evidence that nutritional supplementation helps wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], adequate nutrition is imperative for the prevention of infection which has deleterious effects on wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H122623110\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, we prefer to screen for malnourishment with prealbumin and albumin and optimize nutritional status. Prealbumin and albumin are not perfect markers of nutritional status; however, these should be obtained on patients with nonhealing wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122623110\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of infection impairs several steps of the wound healing process [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/43\">",
"     43",
"    </a>",
"    ]. Bacteria produce inflammatory mediators that inhibit the inflammatory phase of wound healing and prevent epithelialization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1070222553\">",
"     'Inflammation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1070222560\">",
"     'Epithelialization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368952180\">",
"    <span class=\"h2\">",
"     Smoking and nicotine replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is associated with adverse outcomes following surgery, including surgical site infection and pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/46\">",
"     46",
"    </a>",
"    ]. Pulmonary complications and smoking cessation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H4#H4\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The constituents of tobacco smoke and mechanisms responsible for the vasoactive and other effects of smoking have not been fully elucidated; for many years, nicotine was presumed to be responsible, but other constituents of tobacco smoke may have a greater impact. Tobacco smoke is a complex mixture of compounds (eg, nicotine, carbon monoxide, tar, hydrogen cyanide, nitrogen oxides, N-nitrosamines, formaldehyde, benzene) several of which have a physiological impact [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. The detrimental effect of smoking on wound healing is multifactorial with mechanisms that include vasoconstriction causing a relative ischemia of operated tissues, a reduced inflammatory response, impaired bacteriocidal mechanisms, and alterations of collagen metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/47\">",
"     47",
"    </a>",
"    ]. These are postulated to impair wound healing and cause wound dehiscence and incisional hernia. (See",
"    <a class=\"local\" href=\"#H1070222546\">",
"     'Phases of wound healing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Active smoking is associated with postoperative wound healing complications more often in smokers compared with nonsmokers, and in former smokers compared with those who never smoked. A systematic review identified four randomized trials that evaluated the impact of preoperative smoking cessation on postoperative wound healing. Preoperative smoking cessation significantly reduced the incidence of surgical site infection (odds ratio 0.40, 95% CI 0.20-0.83), but did not impact the incidence of other postoperative wound complications (OR 0.48, 95% CI 0.19-1.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/50\">",
"     50",
"    </a>",
"    ]. In a separate study, current or past smoking was associated with an increased risk for postoperative infection (OR 1.9, CI 1.0-3.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although smoking-induced vasoconstriction, mediated by nicotine, can reduce blood flow by up to 40 percent, the effect appears to be temporary with tissue blood flow and oxygen levels restored to normal levels within 45 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Most tissues with an adequate blood supply probably tolerate these transient alterations; however, tissue flaps, which have a fragile blood supply, and other ischemic tissues (eg, moderate to severe peripheral artery disease) may be vulnerable to smoking-induced reductions in blood flow. With respect to other effects of nicotine, both impaired and stimulated wound healing have been identified in experimental studies; however, no clinically significant detrimental or beneficial effects on wound healing have been demonstrated with the use of nicotine replacement therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5177/abstract/56-63\">",
"     56-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations on smoking cessation and nicotine replacement therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55266237\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other etiologies that can lead to skin breakdown and chronic ulceration include conditions that cause vascular inflammation, obstruction or thrombosis at the microvascular level. The final common pathway that produces ulceration or poor wound healing in these disorders is tissue ischemia. (See",
"    <a class=\"local\" href=\"#H55264869\">",
"     'Impaired wound healing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These conditions include cholesterol embolism, vasculitis, pyoderma gangrenosum, polyarteritis nodosum, scleroderma, cryoglobulinemia, Wegner&rsquo;s granulomatosis, thromboangiitis obliterans, warfarin-associated necrosis, heparin-induced thrombocytopenia, protein C deficiency, protein S deficiency and antiphospholipid antibody syndrome. The cutaneous manifestations of these diseases are discussed in separate topic reviews. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603287521\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wound is a disruption of the normal structure and function of the epidermis. Wounds may be caused by a variety of mechanisms including acute injury (abrasion, puncture, crush), surgery or other factors that cause breakdown of previously intact skin (eg, ischemia, pressure). (See",
"      <a class=\"local\" href=\"#H1070222483\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1070222490\">",
"       'Wound mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific time frame that distinguishes between acute and chronic wounds. Chronic wounds are associated with physiologic derangements that impair the wound healing process. (See",
"      <a class=\"local\" href=\"#H1070222490\">",
"       'Wound mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After hemostasis has been achieved, acute wounds normally heal in an orderly and efficient manner characterized by four distinct, but overlapping, phases: inflammation, epithelialization, fibroplasia, and maturation. (See",
"      <a class=\"local\" href=\"#H1070222546\">",
"       'Phases of wound healing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many disease states alter the process of wound healing, the most common of which are peripheral artery disease, diabetes, and chronic venous disease. Small vessel arterial diseases are also associated with the development of skin ulcers and poor wound healing due to vascular obstruction or vascular thrombosis. Other factors that contribute to skin or surgical wound breakdown, or non-healing ulcers include immobility, impaired nutrition, immune suppression and prior radiation therapy. (See",
"      <a class=\"local\" href=\"#H1070222581\">",
"       'Risk factors for non-healing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Orr JW, Taylor PT. Wound healing. In: Complications in gynecological surgery: Prevention, recognition, and management, JB Lippincott, Philadelphia  p.167.",
"    </li>",
"    <li>",
"     Lipscomb, GH, Ling, FG. Wound Healing, Suture Material, and Surgical Instrumentation. In: TeLinde's Operative Gynecology, 9th edition, Rock, JA, Jones, HA, III (Eds), 2003. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/3\">",
"      Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/4\">",
"      Leibovich SJ, Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 1975; 78:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/5\">",
"      Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/6\">",
"      Odland G, Ross R. Human wound repair. I. Epidermal regeneration. J Cell Biol 1968; 39:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/7\">",
"      Ross R, Everett NB, Tyler R. Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J Cell Biol 1970; 44:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/8\">",
"      Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007; 257:143.",
"     </a>",
"    </li>",
"    <li>",
"     Attinger CE, Steinberg JS, Meyr AJ. Debridement of the Diabetic Foot Wound. In: Clinical Care of the Diabetic Foot, Second Edition, Armstrong DG, Lavery LA.  (Eds), American Diabetes Association, Alexandria 2010. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/10\">",
"      Doillon CJ, Dunn MG, Bender E, Silver FH. Collagen fiber formation in repair tissue: development of strength and toughness. Coll Relat Res 1985; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/11\">",
"      Haukipuro K. Synthesis of collagen types I and III in reincised wounds in humans. Br J Surg 1991; 78:708.",
"     </a>",
"    </li>",
"    <li>",
"     Howes, EL, Harvey, SC. The strength of the healing wound in relation to the holding strength of the catgut suture. N Engl J Med 1929; 200:1285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/13\">",
"      Dodson MK, Magann EF, Meeks GR. A randomized comparison of secondary closure and secondary intention in patients with superficial wound dehiscence. Obstet Gynecol 1992; 80:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/14\">",
"      Walters MD, Dombroski RA, Davidson SA, et al. Reclosure of disrupted abdominal incisions. Obstet Gynecol 1990; 76:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/15\">",
"      Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/16\">",
"      Morbach S, Furchert H, Gr&ouml;blinghoff U, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care 2012; 35:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/17\">",
"      Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003; 26:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/18\">",
"      Santilli JD, Santilli SM. Chronic critical limb ischemia: diagnosis, treatment and prognosis. Am Fam Physician 1999; 59:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/19\">",
"      Deatrick KB, Wakefield TW, Henke PK. Chronic venous insufficiency: current management of varicose vein disease. Am Surg 2010; 76:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/20\">",
"      Kurd SK, Hoffstad OJ, Bilker WB, Margolis DJ. Evaluation of the use of prognostic information for the care of individuals with venous leg ulcers or diabetic neuropathic foot ulcers. Wound Repair Regen 2009; 17:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/21\">",
"      Mendelsohn FA, Divino CM, Reis ED, Kerstein MD. Wound care after radiation therapy. Adv Skin Wound Care 2002; 15:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/22\">",
"      Bowering CK. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Can Fam Physician 2001; 47:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/23\">",
"      Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/24\">",
"      Browse NL, Burnand KG. The cause of venous ulceration. Lancet 1982; 2:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/25\">",
"      Franzeck UK, Haselbach P, Speiser D, Bollinger A. Microangiopathy of cutaneous blood and lymphatic capillaries in chronic venous insufficiency (CVI). Yale J Biol Med 1993; 66:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/26\">",
"      Franzeck UK, Bollinger A, Huch R, Huch A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 1984; 70:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/27\">",
"      Mourad MM, Barton SP, Marks R. Changes in endothelial cell mass, luminal volume and capillary number in the gravitational syndrome. Br J Dermatol 1989; 121:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/28\">",
"      Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J (Clin Res Ed) 1982; 285:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/29\">",
"      Butler CM, Coleridge Smith PD. Microcirculatory aspects of venous ulceration. J Dermatol Surg Oncol 1994; 20:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/30\">",
"      Leach RD, Browse NL. Effect of venous hypertension on canine hind limb lymph. Br J Surg 1985; 72:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/31\">",
"      Falanga V, Eaglstein WH. The \"trap\" hypothesis of venous ulceration. Lancet 1993; 341:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/32\">",
"      Reddy M. Skin and wound care: important considerations in the older adult. Adv Skin Wound Care 2008; 21:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/33\">",
"      Fore J. A review of skin and the effects of aging on skin structure and function. Ostomy Wound Manage 2006; 52:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/34\">",
"      Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. Adv Skin Wound Care 2004; 17:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/35\">",
"      Erinjeri JP, Fong AJ, Kemeny NE, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011; 117:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/36\">",
"      Regan MA, Teasell RW, Wolfe DL, et al. A systematic review of therapeutic interventions for pressure ulcers after spinal cord injury. Arch Phys Med Rehabil 2009; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/37\">",
"      Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. Curr Diab Rep 2005; 5:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/38\">",
"      Heinen MM, van Achterberg T, op Reimer WS, et al. Venous leg ulcer patients: a review of the literature on lifestyle and pain-related interventions. J Clin Nurs 2004; 13:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/39\">",
"      Wilkinson EA. Oral zinc for arterial and venous leg ulcers. Cochrane Database Syst Rev 2012; 8:CD001273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/40\">",
"      Raffoul W, Far MS, Cayeux MC, Berger MM. Nutritional status and food intake in nine patients with chronic low-limb ulcers and pressure ulcers: importance of oral supplements. Nutrition 2006; 22:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/41\">",
"      Arnold M, Barbul A. Nutrition and wound healing. Plast Reconstr Surg 2006; 117:42S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/42\">",
"      Abu-Rumman PL, Armstrong DG, Nixon BP. Use of clinical laboratory parameters to evaluate wound healing potential in diabetes mellitus. J Am Podiatr Med Assoc 2002; 92:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/43\">",
"      Freedman G, Cean C, Duron V, et al. Pathogenesis and treatment of pain in patients with chronic wounds. Surg Technol Int 2003; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/44\">",
"      Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/45\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/46\">",
"      Turan A, Mascha EJ, Roberman D, et al. Smoking and perioperative outcomes. Anesthesiology 2011; 114:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/47\">",
"      S&oslash;rensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012; 255:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/48\">",
"      Harris JE. Smoke yields of tobacco-specific nitrosamines in relation to FTC tar level and cigarette manufacturer: analysis of the Massachusetts Benchmark Study. Public Health Rep 2001; 116:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/49\">",
"      Bodnar JA, Morgan WT, Murphy PA, Ogden MW. Mainstream smoke chemistry analysis of samples from the 2009 US cigarette market. Regul Toxicol Pharmacol 2012; 64:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/50\">",
"      S&oslash;rensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg 2012; 147:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/51\">",
"      Wukich DK, McMillen RL, Lowery NJ, Frykberg RG. Surgical site infections after foot and ankle surgery: a comparison of patients with and without diabetes. Diabetes Care 2011; 34:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/52\">",
"      Monfrecola G, Riccio G, Savarese C, et al. The acute effect of smoking on cutaneous microcirculation blood flow in habitual smokers and nonsmokers. Dermatology 1998; 197:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/53\">",
"      S&oslash;rensen LT, J&oslash;rgensen S, Petersen LJ, et al. Acute effects of nicotine and smoking on blood flow, tissue oxygen, and aerobe metabolism of the skin and subcutis. J Surg Res 2009; 152:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/54\">",
"      Black CE, Huang N, Neligan PC, et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/55\">",
"      Jensen JA, Goodson WH, Hopf HW, Hunt TK. Cigarette smoking decreases tissue oxygen. Arch Surg 1991; 126:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/56\">",
"      M&oslash;ller AM, Villebro N, Pedersen T, T&oslash;nnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002; 359:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/57\">",
"      Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Ann Surg 2003; 238:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/58\">",
"      M&oslash;ller AM, Kjellberg J, Pedersen T. [Health economic analysis of smoking cessation prior to surgery--based on a randomised trial]. Ugeskr Laeger 2006; 168:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/59\">",
"      S&oslash;rensen LT, J&oslash;rgensen T. Short-term pre-operative smoking cessation intervention does not affect postoperative complications in colorectal surgery: a randomized clinical trial. Colorectal Dis 2003; 5:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/60\">",
"      S&oslash;rensen LT, Zillmer R, Agren M, et al. Effect of smoking, abstention, and nicotine patch on epidermal healing and collagenase in skin transudate. Wound Repair Regen 2009; 17:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/61\">",
"      S&oslash;rensen LT, Toft B, Rygaard J, et al. Smoking attenuates wound inflammation and proliferation while smoking cessation restores inflammation but not proliferation. Wound Repair Regen 2010; 18:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/62\">",
"      S&oslash;rensen LT, Toft BG, Rygaard J, et al. Effect of smoking, smoking cessation, and nicotine patch on wound dimension, vitamin C, and systemic markers of collagen metabolism. Surgery 2010; 148:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5177/abstract/63\">",
"      S&oslash;rensen LT, Jorgensen LN, Zillmer R, et al. Transdermal nicotine patch enhances type I collagen synthesis in abstinent smokers. Wound Repair Regen 2006; 14:247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15080 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5177=[""].join("\n");
var outline_f5_3_5177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H603287521\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222483\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222490\">",
"      WOUND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222546\">",
"      PHASES OF WOUND HEALING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55260958\">",
"      Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222553\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222560\">",
"      Epithelialization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222567\">",
"      Fibroplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222574\">",
"      Maturation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55264869\">",
"      IMPAIRED WOUND HEALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1070222581\">",
"      RISK FACTORS FOR NON-HEALING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266167\">",
"      Peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266174\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266181\">",
"      Chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122623182\">",
"      Aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266188\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266195\">",
"      Cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55270692\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55270700\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266202\">",
"      Spinal cord disease and immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266216\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122623110\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368952180\">",
"      Smoking and nicotine replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55266237\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603287521\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15080|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/3/35894\" title=\"algorithm 1\">",
"      Phases of wound healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15080|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/60/23498\" title=\"figure 1\">",
"      Skin healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/39/18046\" title=\"figure 2\">",
"      Wound healing time line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/9/28826\" title=\"figure 3\">",
"      Wound healing schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/63/16378\" title=\"figure 4\">",
"      Wound healing granulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/28/37320\" title=\"figure 5\">",
"      Summary of the healing process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/7/26751\" title=\"figure 6\">",
"      Collagen synthesis and tenisle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15080|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/37/32341\" title=\"picture 1\">",
"      Full-thickness wound epithelialization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/29/3542\" title=\"picture 2\">",
"      Common wound constituents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19895\" title=\"picture 3\">",
"      Myofibroblast on electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/45/25304\" title=\"picture 4\">",
"      Fibroblast on electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/1/17430\" title=\"picture 5\">",
"      Wound repigmentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=related_link\">",
"      Clinical assessment of wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=related_link\">",
"      Overview of topical hemostatic agents used in the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=related_link\">",
"      Overview of upper extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_3_5178="Approach to the adult patient with a bleeding diathesis";
var content_f5_3_5178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult patient with a bleeding diathesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/3/5178/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/3/5178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding that is spontaneous, excessive, or delayed in onset following tissue injury results from a localized pathologic process or a disorder of the hemostatic process, involving a complex interplay among vascular integrity, platelet number and function, coagulation factors, and fibrinolysis. This topic review will discuss the diagnostic approach to the patient with abnormal bleeding.",
"   </p>",
"   <p>",
"    Congenital and acquired disorders of platelet function, as well as the hemostatic process and associated disorders, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"       \"Approach to the adult patient with thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"       \"Congenital and acquired disorders of platelet function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"       \"Disorders of fibrinogen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation of a patient with a bleeding disorder begins with a careful history. Patients with inherited hemostatic disorders may report little bleeding, while others without inherited or acquired hemostatic abnormalities may report exaggerated tendencies to bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Given the variability in patients' perceptions of bleeding, as well as the lack of a uniform clinical measure of bleeding severity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/3\">",
"     3",
"    </a>",
"    ], a dialogue between the patient and physician is essential for the consideration of a bleeding diathesis. A careful assessment of the presenting complaint can provide important clues as to where a defect might reside in the hemostatic process and whether the defect is inherited or acquired, providing a rational approach to laboratory investigation (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ). Use of a standardized bleeding assessment tool may help in the prospective evaluation of patients referred for hemostatic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bleeding history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suspected bleeding disorder should be questioned about past bleeding problems, a history of iron-responsive anemia, bleeding outcomes following surgical procedures and tooth extractions, history of transfusion, character of menses, and dietary habits or antibiotic use which might predispose to vitamin K deficiency. The patient should also be questioned concerning the presence of thyroid, liver, and kidney disease. Complaints such as hematuria, melena, and menorrhagia are often less helpful, since structural causes are more commonly responsible than a bleeding diathesis.",
"   </p>",
"   <p>",
"    The response to trauma is an excellent screening test. A history of surgical procedures or tooth extractions or significant injury without abnormal bleeding is good evidence against the presence of an inherited hemorrhagic disorder.",
"   </p>",
"   <p>",
"    An inherited disorder is suggested by the onset of bleeding shortly after birth or during childhood and a positive family history with a consistent genetic pattern. Thus, hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) are characterized by X-linked recessive inheritance. However, a negative family history does not exclude an inherited coagulation disorder. As an example, up to 30 to 40 percent of patients with hemophilia A have a negative family history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of hemophilia\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medication use",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history of medication use is important, including prescribed medications, over-the-counter medications, and herbal products. Drug ingestion may be associated with a bleeding diathesis via a variety of mechanisms, such as the induction of thrombocytopenia or platelet dysfunction, aplastic anemia, or vascular purpura. In addition, some drugs can induce or exacerbate a coagulation disorder. Examples include platelet dysfunction induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other commonly used antiinflammatory drugs, beta-lactam antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and the co-ingestion of drugs that may potentiate the anticoagulant effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An example of the co-ingestion of drugs potentiating the incidence of bleeding was provided in a study of over 21,000 elderly patients recovering from an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, the rates of hospitalization for bleeding (incidence rate per 100 patients per year) for various combinations of antiplatelet agents and anticoagulants were [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      alone &mdash; 3.2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      alone &mdash; 5.9",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      &mdash; 6.8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &mdash; 8.3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study in 27,058 older adult patients discharged following acute myocardial infarction found the following rates of hospitalization for bleeding associated with a different combination of drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , SSRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      alone &mdash; 0.65",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      alone &mdash; 1.55",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus a selective serotonin reuptake inhibitor (SSRI) &mdash; 1.61",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      &mdash; 2.08",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      plus SSRI &mdash; 2.43",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus SSRI &mdash; 3.63",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of disordered hemostasis can be divided into two major categories: those associated with disorders of blood vessels or qualitative or quantitative platelet abnormalities; and those associated with disorders of coagulation (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disorders of platelets or blood vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;These conditions are often referred to as disorders of primary hemostasis or the purpuric disorders since they are characteristically associated with mucosal and cutaneous bleeding (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ). Mucosal bleeding may be manifest as epistaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gingival bleeding, and large bullous hemorrhages may appear on the buccal mucosa due to the lack of vessel protection afforded by the submucosal tissue. Bleeding into the skin is manifested as petechiae or superficial ecchymoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with platelet abnormalities tend to bleed immediately after vascular trauma and rarely experience delayed bleeding, which is more common in the coagulation disorders. The following are the types of bleeding most often associated with these disorders:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Petechiae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Petechiae are small capillary hemorrhages. They characteristically develop in crops in areas of increased venous pressure, such as the dependent parts of the body. As a result, they are most dense on the feet and ankles, fewer are present on the legs (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ). Petechiae are not found on the sole of the foot where the vessels are protected by the strong subcutaneous tissue. They are asymptomatic and not palpable, and should be distinguished from small telangiectasias, angiomas, and vasculitic purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ecchymoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecchymotic lesions characteristically are purple in color and are small, multiple, and superficial in location. They usually develop without noticeable trauma and do not spread into deeper tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menorrhagia (menstrual flow that does not taper after more than three days) and metrorrhagia (bleeding in between periods) are common in women with bleeding disorders; up to 15 to 20 percent of women presenting with menorrhagia may have some type of bleeding diathesis, such as von Willebrand disease, immune thrombocytopenia (ITP), platelet function defect [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coagulation disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical manifestations of bleeding in the coagulation disorders are large palpable ecchymoses and large, spreading, deep soft tissue hematomas.",
"   </p>",
"   <p>",
"    Hemorrhage into synovial joints (hemarthrosis) most often indicates a severe inherited coagulation disorder, such as hemophilia (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ). Postsurgical bleeding can be extensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients with a coagulation disorder, the onset of bleeding after trauma may be delayed. As an example, bleeding after a tooth extraction may stop, only to recur in a matter of hours. The reason for this phenomenon and for the absence of petechiae or bleeding from small cuts or scratches is the preservation of normal platelet function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26266204\">",
"    <span class=\"h2\">",
"     The cardiac surgery patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient undergoing cardiac surgery can be difficult due to competing bleeding and thrombotic tendencies. Abnormalities which may occur in such patients include some or all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endothelial",
"      <span class=\"nowrap\">",
"       damage/activation",
"      </span>",
"      with disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Presence of prosthetic valves, stents, vascular grafts, assist devices",
"     </li>",
"     <li>",
"      Use of antiplatelet",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticoagulant agents",
"     </li>",
"     <li>",
"      Intraoperative metabolic abnormalities (eg, hypothermia, acidosis, anemia, hypocalcemia)",
"     </li>",
"     <li>",
"      Presence of associated hepatic or renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests of primary and secondary hemostatic mechanisms are used for two purposes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General screening tests",
"     </li>",
"     <li>",
"      Tests to define specific platelet or clotting factor abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General screening tests include the platelet count, bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT).",
"   </p>",
"   <p>",
"    Specific tests include examination of the peripheral blood smear, platelet aggregation in response to ADP, epinephrine, collagen, and ristocetin; platelet release assays, coagulation factor assays, and assessment of factor XIII activity via clot solubility testing. Tests of fibrinolysis include the measurement of fibrin split products and D-dimer levels. Assays for the less commonly seen bleeding disorders include alpha-2-antiplasmin activity, euglobulin clot lysis time, as well as tissue plasminogen activator and plasminogen activator inhibitor-1 antigens.",
"   </p>",
"   <p>",
"    Appropriate emergency laboratory testing for those with active bleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H22#H22\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Platelet counting and the peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets may be counted directly or with the use of fully automated electronic methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    .) While some automated methods may flag for the presence of unusually small or extremely large platelets, there is no substitute for direct examination of the peripheral blood smear for detection of quantitative as well as qualitative (ie, abnormalities of platelet size) platelet abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'CBC and peripheral smear examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the peripheral blood smear is essential in patients with low platelet counts to exclude the presence of pseudothrombocytopenia due to in vitro platelet agglutination in the presence of EDTA&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 2",
"    </a>",
"    ). This phenomenon is thought to result from a \"naturally occurring\" platelet autoantibody directed against a normally concealed epitope on the platelet membrane, which becomes exposed by EDTA. Use of alternative anticoagulants (eg, citrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ), may circumvent this technical problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bleeding time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bleeding time (BT) is a measure of the interaction of platelets with the blood vessel wall. A prolonged bleeding time may occur in thrombocytopenia (platelet count usually below",
"    <span class=\"nowrap\">",
"     50,000/microL),",
"    </span>",
"    qualitative platelet abnormalities (eg, uremia), von Willebrand disease (VWD), some cases of vascular purpura, and severe fibrinogen deficiency, in which it is probably the result of platelet dysfunction. Among patients with a normal platelet count who are not taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the bleeding time is used primarily to screen patients for inherited disorders of platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An abnormal test in a patient with mucocutaneous bleeding would justify further testing for platelet dysfunction or specific tests for von Willebrand disease (VWD). However, a normal value for the BT should not preclude testing for VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. As will be discussed below, the Platelet Function Analyzer is more sensitive for detection of VWD than is the BT (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal BT does not predict the safety of surgical procedures, nor does an abnormal BT predict for excessive bleeding. Since assessment of the BT is subject to considerable variation due to technical factors in executing the test, a normal range for the test varies from laboratory to laboratory, and cannot be generalized here. Of importance, the BT is",
"    <strong>",
"     not recommended",
"    </strong>",
"    as a preoperative screening test. Because of considerable variation due to technical factors in executing the test, the BT plays a limited role, if any,&nbsp;in evaluating hemostatic defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H7#H7\">",
"     \"Preoperative assessment of hemostasis\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The Platelet Function Analyzer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commercially-available Platelet Function Analyzer (PFA-100) is an alternative technology that assesses platelet function with greater sensitivity and reproducibility than the bleeding time (BT) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/15\">",
"     15",
"    </a>",
"    ]. Because the BT is insensitive, invasive, time consuming, and subject to variation due to technical factors, many centers have adopted the PFA-100 in place of the BT as their screening test of platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"     \"Platelet function testing\", section on 'The platelet function analyzer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This test may be performed on citrated samples of whole blood that have been stored at room temperature, and is considerably faster to perform than platelet aggregation studies. Normal PFA-100 test results may obviate the need for further expensive platelet function testing. Unlike the in vivo BT, the PFA-100 test does not provide a measure of vascular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prothrombin time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production of fibrin via the extrinsic pathway and the final common pathway (common to both extrinsic and intrinsic cascades) requires tissue thromboplastin (tissue factor), factor VII (extrinsic pathway), and factors X, V, prothrombin (factor II), and fibrinogen. The functioning of these pathways is measured by the plasma prothrombin time (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ). The test bypasses the intrinsic pathway and uses thromboplastins to substitute for platelets. Within this combined pathway, factors VII, X, and prothrombin are vitamin-K dependent and are altered by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . For this reason, the PT is used as a measure of oral anticoagulant activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical use of coagulation tests\", section on 'Prothrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Activated partial thromboplastin time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways of coagulation (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ). It is called partial since platelet substitutes are used which are only partial thromboplastins; they are incapable of activating the extrinsic pathway, which requires complete tissue thromboplastin (tissue factor). In the original method, a glass test tube provided contact activation. However, the addition of activators such as ellagic acid or particulate silicates provided better and more standardized contact activation. This activated version of the PTT (aPTT) is now the routine assay used to evaluate intrinsic coagulation and the degree of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical use of coagulation tests\", section on 'Activated partial thromboplastin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aPTT is sensitive to inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and to deficiencies of all coagulation factors except factors VII and XIII. It is less sensitive than the PT to deficiencies of the common pathway (factors X and V, prothrombin, and fibrinogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/18\">",
"     18",
"    </a>",
"    ]. High levels of a single factor (eg, factor VIII) can shorten the aPTT. However, an association between a short aPTT and a hypercoagulable state remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thrombin time and reptilase time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombin time (TT) and reptilase time (RT) measure conversion of fibrinogen to fibrin monomers and the formation of initial clot by thrombin and reptilase, respectively. Reptilase, a thrombin-like snake enzyme, differs from thrombin by generating fibrinopeptide A but not fibrinopeptide B from fibrinogen and by resisting inhibition by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    via antithrombin. Fibrin strand cross-linking, which is mediated by factor XIII, is not measured by these assays.",
"   </p>",
"   <p>",
"    Prolonged thrombin times and reptilase times may be due to hypofibrinogenemia, structurally abnormal fibrinogens (dysfibrinogens), or increased fibrin split products [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/19\">",
"     19",
"    </a>",
"    ]. Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prolongs the TT but not the RT, the RT is useful for determining if heparin is the cause of a prolonged TT. Alternatively, one can test for heparin activity via its anti-factor Xa activity, or with the use of a commercial heparinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical use of coagulation tests\", section on 'Heparin in the sample'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Factor deficiencies and inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged aPTT can be due to a deficiency (or absence) of a coagulation factor or the presence of a coagulation factor inhibitor. A factor deficiency should be correctable by addition of normal plasma to the test reaction tube. This is normally done by performing a PT or aPTT on a 1:1 mixture of patient and normal plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical use of coagulation tests\", section on 'Mixing studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific factor deficiencies are then determined by assessing the PT or aPTT in mixes of test plasma with commercially available plasmas deficient in known factors. Factor levels can be functionally assessed by comparing test results to standard curves generated by mixtures of serially diluted normal plasma and factor-deficient plasma. Immunologic assays can also be used to measure factor levels. Immunologic and functional assays should give equivalent results when a factor deficiency is present. On the other hand, a low functional assay but normal immunologic assay indicates the presence of a functionally abnormal factor.",
"   </p>",
"   <p>",
"    The presence of a factor inhibitor is suspected when the abnormal test does not correct, or only partially corrects, following an immediate assay of a 1:1 mixture of patient and normal plasma. In some cases, such as acquired factor VIII antibodies, the aPTT may correct immediately after mixing, but becomes prolonged after 60 to 120 minutes of incubation at 37&ordm;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical use of coagulation tests\", section on 'Mixing studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to factor inhibitors, lupus anticoagulants can result in a prolonged aPTT that is not correctable by the addition of normal plasma. The effect of these antibodies on the aPTT can be overcome by adding excess platelet phospholipid (particularly a hexagonal phase phospholipid) or by assessing the diluted Russell's viper venom time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/20\">",
"     20",
"    </a>",
"    ]. Paradoxically, the antiphospholipid syndrome is usually associated with a tendency to thrombosis rather than bleeding; the prolonged aPTT is an artifact of the antiphospholipid phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Anticardiolipin antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fibrinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen's functional activity is measured as thrombin-coagulable protein, while levels of structural fibrinogen are measured by immunologic assays. Immunologic and functional assays of fibrinogen may be discordant in patients with an inherited dysfibrinogenemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H26#H26\">",
"     \"Disorders of fibrinogen\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Urea clot solubility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial fibrin clot, held together by noncovalent bonds, is soluble in urea. Subsequent transglutamination by factor XIII covalently crosslinks overlapping fibrin strands, which then become resistant to solubilization. The ability of 5M urea or monochloroacetic acid to solubilize the clot reflects deficiency of factor XIII (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tests for fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin and fibrinogen degradation products (FDP) are protein fragments resulting from the action of plasmin on fibrin or fibrinogen, respectively. Elevated levels are seen in states of fibrinolysis such as disseminated intravascular coagulation (DIC). FDP assays do not differentiate between fibrin degradation products and fibrinogen degradation products. It is possible to accurately measure the concentration of fibrin D-dimers, which are degradation products of cross-linked fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/21\">",
"     21",
"    </a>",
"    ]. The method of choice is the enzyme-linked immunosorbent assay (ELISA).",
"   </p>",
"   <p>",
"    When fibrinolysis exceeds thrombin generation, thereby increasing the risk of hemorrhage rather than thrombosis (eg, disseminated intravascular coagulation associated with acute promyelocytic leukemia), quantitative FDP levels may be more sensitive than D-dimer levels as an indication of the degree of fibrinolytic activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link&amp;anchor=H14#H14\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\", section on 'Microangiopathic hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because D-dimers specifically reflect fibrinolysis of cross-linked fibrin (ie, the fibrin clot), assessment of D-dimer levels suggests thrombosis more reliably. As an example, in patients who have a low pretest probability of deep vein thrombosis, the negative predictive value of D-dimers is high [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'D-dimer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The euglobulin lysis time, which assesses overall fibrinolysis is less useful, since results from this test may vary significantly in relation to calcium ion concentrations as well as plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Alpha-2 antiplasmin, an inhibitor of fibrinolysis, is not measured in this test.",
"   </p>",
"   <p>",
"    More specific tests of the fibrinolytic system include assays for plasminogen, tissue plasminogen activator (t-PA), alpha-2 antiplasmin, plasminogen activator inhibitor-1 (PAI-1), and thrombin-activatable fibrinolysis inhibitor (TAFI). Assays for alpha-2 antiplasmin are used clinically to identify patients with alpha-2 antiplasmin deficiency, an inherited disorder associated with delayed bleeding. However, specific assays for t-PA, PAI-1 and TAFI are of uncertain use clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients with a bleeding diathesis, the likely diagnosis will be apparent from the history and physical examination; the diagnosis can then be confirmed with the appropriate specific tests (",
"    <a class=\"graphic graphic_table graphicRef88913 \" href=\"UTD.htm?33/8/33932\">",
"     table 2",
"    </a>",
"    ). Individual tests (eg, either PT or aPTT alone) can also be used for monitoring the effect of an anticoagulant or assessing patients with a known condition that has a predictable effect on coagulation.",
"   </p>",
"   <p>",
"    When the diagnosis is not immediately apparent, three initial tests should be performed&mdash;platelet count, PT, and aPTT&mdash;because defects in primary or secondary hemostasis, including intrinsic, extrinsic, and common pathway defects, can all be responsible for bleeding (",
"    <a class=\"graphic graphic_table graphicRef88913 \" href=\"UTD.htm?33/8/33932\">",
"     table 2",
"    </a>",
"    ). The pattern of results provides a presumptive diagnosis which can then be confirmed with specific testing (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67121 \" href=\"UTD.htm?36/13/37084\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Normal PT and aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia with a normal PT and aPTT is the most common of the acquired bleeding disorders. In the presence of significant thrombocytopenia, the bleeding time is prolonged and clot retraction is deficient. Measurement of the bleeding time or PFA-100 (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Bleeding time'",
"    </a>",
"    above) is not necessary in patients who have platelet counts below",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bleeding time or PFA-100 test (see",
"    <a class=\"local\" href=\"#H14\">",
"     'The Platelet Function Analyzer'",
"    </a>",
"    above) should be measured in patients with a history of mucocutaneous bleeding who have a normal platelet count, PT, and aPTT. A prolonged bleeding time or PFA-100 justifies further platelet function testing, including assays to evaluate von Willebrand disease (VWD) and platelet aggregation studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .) However, a normal bleeding time should not preclude evaluation for VWD, especially since the PFA-100 test has substantially higher sensitivity for detecting VWD than the bleeding time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare cause of bleeding associated with normal PT, aPTT, and TT is factor XIII deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H26#H26\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Factor XIII deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     vWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;von Willebrand disease (VWD) is the most common inherited bleeding disorder, with an estimated prevalence of up to 1 percent. A small number of patients have been described with acquired VWD due to antibodies, usually associated with autoimmune or clonal proliferative disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with VWD present with moderate to severe mucocutaneous bleeding due to reduced levels of von Willebrand factor (VWF). They may have a prolonged aPTT due to a mild to moderate concordant deficiency of factor VIII (",
"    <a class=\"graphic graphic_table graphicRef67121 \" href=\"UTD.htm?36/13/37084\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/27\">",
"     27",
"    </a>",
"    ]. In some patients, however, the clinical manifestations are mild, the aPTT is normal, and further studies are necessary to make the diagnosis. This is particularly true when factors which increase VWF and factor VIII levels (eg, pregnancy, oral contraceptive use, liver disease) are present. In such cases, the test should be repeated when these conditions are no longer present.",
"   </p>",
"   <p>",
"    Useful tests include bioassay of factor VIII, immunoassay of VWF antigen, and measurement of ristocetin cofactor activity. Repeated testing is required to establish the diagnosis of VWD because test results may vary over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Platelet dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies to confirm the presence of qualitative disorders of platelet function include evaluation of platelet morphology, and tests of platelet aggregation and function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inherited disorders of platelet function are relatively rare and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bernard-Soulier syndrome &mdash; characterized by a defect in any of the components of the glycoprotein (GP)",
"      <span class=\"nowrap\">",
"       Ib/IX/V",
"      </span>",
"      complex, giant platelets, and greater than expected bleeding for the degree of thrombocytopenia",
"     </li>",
"     <li>",
"      Glanzmann thrombasthenia &mdash; characterized by a defect in the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      complex, normal platelet counts, normal platelet morphology, and abnormal in vitro platelet aggregation.",
"     </li>",
"     <li>",
"      Storage pool diseases &mdash; these include Wiskott-Aldrich syndrome, thrombocytopenia with absent radii syndrome, Chediak&ndash;Higashi syndrome, and Hermansky-Pudlak syndrome. The much more common acquired causes include use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and nonsteroidal antiinflammatory drugs, beta-lactam antibiotics, uremia, and myeloproliferative and myelodysplastic syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"       \"Platelet dysfunction in uremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"       \"Congenital and acquired disorders of platelet function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders leading to a bleeding diathesis which are associated with normal screening coagulation tests include factor XIII deficiency and rare abnormalities in regulators of plasminogen activation or plasmin degradation (eg, alpha-2 antiplasmin deficiency, plasminogen activator inhibitor-1 deficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factor XIII deficiency presents with delayed bleeding, usually 24 to 36 hours after surgery or trauma. The diagnosis is made by demonstration of clot dissolution in 5 molar urea or monochloroacetic acid (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/29\">",
"     29",
"    </a>",
"    ]. As noted above, patients with VWD may have normal screening test results (eg, normal PT, aPTT, and BT).",
"   </p>",
"   <p>",
"    The clinical relevance of the factors involved in the initial phase of the intrinsic (also called contact activation) pathway (eg, prekallikrein, HMWK, and factor XII) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of hemostasis\", section on 'Intrinsic pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Vascular purpuras",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the possible exception of a prolonged bleeding time, screening tests are usually normal in patients with bleeding disorders related to vascular abnormalities (",
"    <a class=\"graphic graphic_table graphicRef67121 \" href=\"UTD.htm?36/13/37084\">",
"     table 4",
"    </a>",
"    ). These include structural abnormalities (eg, hereditary hemorrhagic telangiectasia), hereditary disorders of connective tissue (eg, Ehlers-Danlos disease, osteogenesis imperfecta), acquired connective tissue disorders (eg, scurvy, steroid-induced purpura), small vessel vasculitis, and purpura associated with the presence of paraproteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Small vessel vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Unknown cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are encountered with a significant bleeding history for which there is no explanation. Abuse, occasionally self-inflicted, should be considered, but it is likely that some disorders of hemostasis escape detection with currently available methods. Psychogenic purpura may be among these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15048?source=see_link\">",
"     \"Psychogenic purpura (Gardner-Diamond syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Normal PT and prolonged aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal PT and a prolonged aPTT is characteristic of disorders of the intrinsic pathway of coagulation (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). Inherited disorders include deficiencies of factors VIII (hemophilia A, von Willebrand disease), IX (hemophilia B), and XI. Hemophilia A and B are the most common. In one study in six states, the age-adjusted prevalence of hemophilia in 1994 was 13.4",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    males (10.5 for hemophilia A and 2.9 for B) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients with these disorders present with life-long recurrent soft tissue and joint bleeding, generally requiring frequent factor replacement therapy (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Factor XI deficiency, which is relatively common in Ashkenazi Jews, but can be seen in a variety of ethnic groups, presents with a variable and unpredictable bleeding history [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Bleeding in these patients, when present, is most commonly seen following surgical procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link\">",
"     \"Factor XI deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also a variety of disorders that prolong the aPTT but are not associated with excessive bleeding. These include inherited or acquired factor XII deficiency, as well as deficiencies of prekallikrein or high molecular weight kininogen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Acquired inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired inhibitors include antiphospholipid antibodies which, as noted above, may be associated with thrombosis rather than bleeding, and antibodies to factor VIII (acquired hemophilia), IX, and XI, which may be associated with catastrophic bleeding (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). Factor VIII inhibitors have been described in association with malignancy, clonal lymphoproliferative disorders, pregnancy, rheumatologic disorders, as well as in the absence of underlying disease. Acquired antibodies to factor IX and XI are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .) Acquired inhibitors of factor V may have variable effects on the PT, aPTT, and BT (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Prolonged PT and normal aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged PT with a normal aPTT is indicative of an abnormality in the extrinsic pathway and suggests factor VII deficiency, which can be inherited or acquired (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). Inherited factor VII deficiency displays considerable phenotypic and molecular heterogeneity, and there are inconsistencies between the clinical picture, the underlying clotting and molecular defects, and the response to prophylactic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. The manifestations range from no excessive bleeding to a severe hemorrhagic tendency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/3/5178/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H21#H21\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Factor VII deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired inhibitors of factor VII are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H26#H26\">",
"     \"Acquired inhibitors of coagulation\", section on 'Factor VII inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This pattern is most commonly seen following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, early liver disease, and vitamin K deficiency, and, less commonly, in certain (early) cases of DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858423#H5858423\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Prothrombin time (PT) and the International Normalized Ratio (INR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prolonged PT and aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of both the PT and the aPTT indicates an inherited disorder of the common pathway or a more complex acquired disorder involving multiple pathways (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited disorders include deficiency of factor X, factor V, prothrombin (factor II), or fibrinogen (factor 1). These deficiencies are extremely rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link\">",
"       \"Rare (recessively inherited) coagulation disorders\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Inherited disorders with a low fibrinogen level include afibrinogenemia, a rare autosomal recessive disorder with mucocutaneous bleeding episodes that may abate in severity with age and that are treatable with fibrinogen replacement, and the dysfibrinogenemias, a heterogeneous group of autosomal dominant disorders occasionally associated with either a bleeding or thrombotic diathesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H15#H15\">",
"       \"Disorders of fibrinogen\", section on 'Congenital afibrinogenemia/hypofibrinogenemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supratherapeutic doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      can cause prolongation of both the PT and aPTT. It is common to see prolongation of both the PT and aPTT when heparin and warfarin are employed simultaneously, as in the initial treatment of venous thromboembolic disease.",
"     </li>",
"     <li>",
"      Acquired disorders with multiple abnormalities which produce this pattern include vitamin K deficiency, liver disease, disseminated intravascular coagulation, and fibrinolysis. Differentiating among these possibilities may be difficult. The following may help in distinguishing among these conditions:",
"      <br/>",
"      <br/>",
"      In both liver disease and vitamin K deficiency, there is deficient synthesis of factors II, VII, IX and X. Since factor V production is independent of vitamin K status, low factor V levels can be used as evidence for either reduced hepatic synthetic function or increased consumption, as in DIC. Since factor VIII production is independent of vitamin K status and this factor is not manufactured by hepatocytes; factor VIII levels are usually normal or increased in liver disease. Thus, low levels of factor VIII would favor a diagnosis of DIC in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858414#H5858414\">",
"       \"Coagulation abnormalities in patients with liver disease\", section on 'Tests of coagulation in liver disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acquired inhibitors of factor V have been described, at times in association with topical bovine thrombin therapy. Acquired antibodies to bovine thrombin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      factor V contaminating bovine thrombin preparations may cross-react with endogenous human factor V as well as with human thrombin. Effects of these antibodies on PT, aPTT, and TT testing can vary, and associated risks of bleeding, which can be severe, are unpredictable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H22#H22\">",
"       \"Acquired inhibitors of coagulation\", section on 'Factor V inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first step in the evaluation of patients with a prolonged PT and aPTT should be to exclude or identify an abnormality of fibrinogen. This can be achieved by measurement of the plasma fibrinogen concentration and the thrombin time, and testing for increased amounts of D-dimer or",
"    <span class=\"nowrap\">",
"     fibrin/fibrinogen",
"    </span>",
"    degradation products (FDP). In patients with an inherited coagulation disorder and normal amounts of fibrinogen, deficiencies of factor V, factor X, and prothrombin can be diagnosed by specific factor assays. In patients with an acquired disorder, the likely diagnosis, in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and fibrinogen abnormalities, is vitamin K deficiency or liver disease.",
"   </p>",
"   <p>",
"    Acquired inhibitors to prothrombin and factor X are extremely rare. Acquired factor X deficiency may be seen in patients with primary amyloidosis, and results from the binding of factor X to amyloid fibrils. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding that is spontaneous, excessive, or delayed in onset following tissue injury results from one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A localized pathologic process",
"     </li>",
"     <li>",
"      Disorders involving vascular integrity",
"     </li>",
"     <li>",
"      Disorders of platelet number",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function",
"     </li>",
"     <li>",
"      Disorders of the various coagulation factors",
"     </li>",
"     <li>",
"      Increased fibrinolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful assessment of the presenting complaint and the patient's bleeding history can provide important clues as to where a defect might reside in the hemostatic process and whether the defect is inherited or acquired (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient history'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H2#H2\">",
"       \"Preoperative assessment of hemostasis\", section on 'The classic approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the adult patient with thrombocytopenia\", section on 'Initial approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The physical examination is helpful in determining the type of bleeding present, as well as for detecting other conditions that might be present. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H5#H5\">",
"       \"Preoperative assessment of hemostasis\", section on 'The physical examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H23#H23\">",
"       \"Approach to the adult patient with thrombocytopenia\", section on 'The physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In many patients the likely diagnosis will be apparent from the history and physical examination alone; the diagnosis can then be confirmed with the appropriate specific tests.",
"     </li>",
"     <li>",
"      When the diagnosis is not immediately apparent, three initial tests should be performed: platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) (",
"      <a class=\"graphic graphic_table graphicRef88913 \" href=\"UTD.htm?33/8/33932\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"       \"Clinical use of coagulation tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pattern of results provides a presumptive diagnosis which can then be confirmed with specific testing (",
"      <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67121 \" href=\"UTD.htm?36/13/37084\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/1\">",
"      Wahlberg T, Blomb&auml;ck M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med 1980; 19:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/2\">",
"      Wahlberg T, Blomb&auml;ck M, Brodin U. Carriers and noncarriers of haemophilia A: I. Multivariate analysis of pedigree data, screening blood coagulation tests and factor VIII variables. Thromb Res 1982; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/3\">",
"      Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004; 44:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/4\">",
"      Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/5\">",
"      Tosetto A, Castaman G, Plug I, et al. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/6\">",
"      Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/7\">",
"      Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/8\">",
"      Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/9\">",
"      Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/10\">",
"      Achneck HE, Sileshi B, Parikh A, et al. Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation 2010; 122:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/11\">",
"      Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/12\">",
"      The bleeding time. Lancet 1991; 337:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/13\">",
"      Gralnick HR, Rick ME, McKeown LP, et al. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. Blood 1986; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/14\">",
"      Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/15\">",
"      Posan E, McBane RD, Grill DE, et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/16\">",
"      Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/17\">",
"      Francis J, Francis D, Larson L, et al. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/18\">",
"      Suchman AL, Griner PF. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med 1986; 104:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/19\">",
"      Ockelford PA, Carter CJ. Disseminated intravascular coagulation: the application and utility of diagnostic tests. Semin Thromb Hemost 1982; 8:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/20\">",
"      Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/21\">",
"      Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Pathol 1987; 87:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/22\">",
"      Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/23\">",
"      Kojima Y, Urano T, Kojima K, et al. The significant enhancement of fibrinolysis by calcium ion in a cell free system: the shortening of euglobulin clot lysis time by calcium ion. Thromb Haemost 1994; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/24\">",
"      Urano T, Sakakibara K, Rydzewski A, et al. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/25\">",
"      Takada A, Takada Y, Urano T, et al. Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma in daytime. Thromb Res 1990; 57:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/26\">",
"      Gudmundsdottir BR, Marder VJ, Onundarson PT. Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. J Thromb Haemost 2007; 5:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/27\">",
"      Kaufman RJ, Dorner AJ, Fass DN. von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood 1999; 93:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/28\">",
"      Abildgaard CF, Suzuki Z, Harrison J, et al. Serial studies in von Willebrand's disease: variability versus \"variants\". Blood 1980; 56:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/29\">",
"      Girolami A, Sartori MT, Simioni P. An updated classification of factor XIII defect. Br J Haematol 1991; 77:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/30\">",
"      Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/31\">",
"      Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/32\">",
"      Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/33\">",
"      L&auml;mmle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/34\">",
"      Mariani G, Lo Coco L, Bernardi F, Pinotti M. Molecular and clinical aspects of factor VII deficiency. Blood Coagul Fibrinolysis 1998; 9 Suppl 1:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/35\">",
"      Pinotti M, Toso R, Redaelli R, et al. Molecular mechanisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene. Blood 1998; 92:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/36\">",
"      Perry DJ. Factor VII Deficiency. Br J Haematol 2002; 118:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/37\">",
"      Castoldi E, Govers-Riemslag JW, Pinotti M, et al. Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G&gt;A (FVII Lazio) mutation. Blood 2003; 102:4014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/38\">",
"      Mathijssen NC, Masereeuw R, Verbeek K, et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/39\">",
"      Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P, et al. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol 2002; 117:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/3/5178/abstract/40\">",
"      Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1367 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5178=[""].join("\n");
var outline_f5_3_5178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bleeding history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medication use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disorders of platelets or blood vessels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Petechiae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ecchymoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26266204\">",
"      The cardiac surgery patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Platelet counting and the peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bleeding time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The Platelet Function Analyzer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prothrombin time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Activated partial thromboplastin time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thrombin time and reptilase time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Factor deficiencies and inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Urea clot solubility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tests for fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Normal PT and aPTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - vWD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Platelet dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Vascular purpuras",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Unknown cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Normal PT and prolonged aPTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Acquired inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Prolonged PT and normal aPTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prolonged PT and aPTT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1367|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 1\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1367|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/8/10372\" title=\"picture 1\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 2\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/8/33932\" title=\"table 2\">",
"      Indications for PT and aPTT testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 3\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/13/37084\" title=\"table 4\">",
"      Test results bleeding disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15048?source=related_link\">",
"      Psychogenic purpura (Gardner-Diamond syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_3_5179="Cutaneous syndrome";
var content_f5_3_5179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The cutaneous syndrome in occult spinal dysraphism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patch of hyperkeratosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patch of hypertrichosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patch of hyperpigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patch of epidermal atrophy (may be tender)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous mass (lipoma or neurofibroma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capillary hemangioma or cutaneous angioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal dermal sinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacrococcygeal pit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacrococcygeal dimple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caudal cutaneous appendage (true tail or pseudotail)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated deviation of the intergluteal fold",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chaouki Khoury, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5179=[""].join("\n");
var outline_f5_3_5179=null;
var title_f5_3_5180="Nonmuscle features myotonic dystrophy I and II";
var content_f5_3_5180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extra-muscular characteristics of myotonic dystrophy (DM), types I and II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of DM",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cataracts",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cardiac abnormalities",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cognitive impairment; personality disturbance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Endocrine disturbance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gastrointestinal disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DM I (Steinert's disease)",
"      </td>",
"      <td>",
"       Very common; almost universal late in course*",
"      </td>",
"      <td>",
"       <p>",
"        Conduction disturbances well recognized and common late in course*",
"       </p>",
"       <p>",
"        Progressive cardiomyopathy also described",
"       </p>",
"      </td>",
"      <td>",
"       Mental retardation (congenital form) is common; mild to moderate cognitive and personality defects in adult form",
"      </td>",
"      <td>",
"       <p>",
"        Glucose intolerance: well recognized and common late in course*",
"       </p>",
"       <p>",
"        Hypogonadism: common and almost universal late in course*",
"       </p>",
"      </td>",
"      <td>",
"       Irritable bowel symptoms; dysphagia; gall stones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DM II (Proximal myotonic myopathy)",
"      </td>",
"      <td>",
"       Common (78% in subjects &gt;50 years)&bull;",
"      </td>",
"      <td>",
"       <p>",
"        Conduction disturbances less problematic than DM I (19 percent when considered across age spectrum [21 - &gt;50]&bull;)",
"       </p>",
"       <p>",
"        Progressive cardiomyopathy also described",
"       </p>",
"      </td>",
"      <td>",
"       Mild cognitive impairment may be seen",
"      </td>",
"      <td>",
"       <p>",
"        Glucose intolerance: common, seen in 75 percent&bull;",
"       </p>",
"       <p>",
"        Hypogonadism: seen in 29 percent&bull;",
"       </p>",
"      </td>",
"      <td>",
"       Yes, but not as pronounced as in DM1; dysphagia common but relatively mild",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Information from Harper PS. Myotonic dystrophy, 2nd edition, WB Saunders, London, 1989.",
"     <br>",
"      &bull; Information from Day JW, Ricker K, Jacobsen BS et al. Myotonic dystrophy type 2. Molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657-664.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5180=[""].join("\n");
var outline_f5_3_5180=null;
var title_f5_3_5181="Major causes of edema by primary mechanism";
var content_f5_3_5181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of edema by primary mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased capillary hydraulic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. Increased plasma volume due to renal Na+ retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Heart failure, including cor pulmonale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Primary renal sodium retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Renal disease, including the nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Drugs: minoxidil, diazoxide, thiazolidinediones, calcium channel blockers (particularly nifedipine), nonsteroidal anti-inflammatory drugs, fludrocortisone, estrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Refeeding edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. Early hepatic cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Pregnancy and premenstrual edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Idiopathic edema, when diuretic induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Cirrhosis or hepatic venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Acute pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Local venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. Decreased arteriolar resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Calcium channel blockers (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Idiopathic edema (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoalbuminemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. Protein loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Protein-losing enteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Reduced albumin synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased capillary permeability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Idiopathic edema (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Inflammation or sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Allergic reactions, including certain forms of angioedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. Adult respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G. Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H. Interleukin-2 therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I. Malignant ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphatic obstruction or increased interstitial oncotic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Lymph node dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Nodal enlargement due to malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Malignant ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Uncertain mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Docetaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Pramipexole",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5181=[""].join("\n");
var outline_f5_3_5181=null;
var title_f5_3_5182="Contents: Cardiovascular Medicine";
var content_f5_3_5182=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Cardiovascular Medicine",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cardiovascular Medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?41/17/42256\">",
"         Acute coronary syndromes",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/60/3014\">",
"         Cardiac arrhythmias",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?33/55/34685\">",
"         Cardiac evaluation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/6/4206\">",
"         Cardiology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/26/27040\">",
"         Cerebrovascular disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/0/23566\">",
"         Congenital heart disease adults",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/6/35942\">",
"         Coronary heart disease",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?39/48/40718\">",
"         Coronary revascularization",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/33/25110\">",
"         Critical care medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/42/28334\">",
"         Electrocardiography",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/26/41389\">",
"         Electrocardiography tutorial",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/5/22609\">",
"         Heart failure",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/34/18990\">",
"         Heart transplantation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/11/8368\">",
"         Hypertension",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?25/43/26302\">",
"         Lipid disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/33/6672\">",
"         Myopericardial disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/29/8671\">",
"         Noninvasive cardiac imaging",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/43/17086\">",
"         Peripheral artery disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?9/50/10016\">",
"         Valvular and aortic disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/19/21817\">",
"         What's new in cardiovascular medicine",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-134335BC29-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_3_5182=[""].join("\n");
var outline_f5_3_5182=null;
var title_f5_3_5183="Secondary prevention early-onset GBS disease among newborns";
var content_f5_3_5183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary prevention of early-onset group B streptococcal (GBS) disease among newborns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 477px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Full diagnostic evaluation includes a blood culture, a complete blood count (CBC) including white blood cell differential and platelet counts, chest radiograph (if respiratory abnormalities are present), and lumbar puncture (if patient is stable enough to tolerate procedure and sepsis is suspected).",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Antibiotic therapy should be directed toward the most common causes of neonatal sepsis, including intravenous ampicillin for GBS and coverage for other organisms (including",
"      <em>",
"       Escherichia coli",
"      </em>",
"      and other gram-negative pathogens) and should take into account local antibiotic resistance patterns.",
"      <br>",
"       &Delta; Consultation with obstetric providers is important to determine the level of clinical suspicion for chorioamnionitis. Chorioamnionitis is diagnosed clinically, and some of the signs are nonspecific.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Limited evaluation includes blood culture (at birth) and CBC with differential and platelets (at birth and/or at 6 to 12 hours of life).",
"        <br>",
"         &sect; Indications for GBS prophylaxis are discussed in the text.",
"         <br>",
"          &yen; If signs of sepsis develop, a full diagnostic evaluation should be conducted and antibiotic therapy initiated.",
"          <br>",
"           &Dagger; If &ge;37 weeks' gestation, observation may occur at home after 24 hours if other discharge criteria have been met, access to medical care is readily available, and a person who is able to comply fully with instructions for home observation will be present. If any of these conditions is not met, the infant should be observed in the hospital for at least 48 hours and until discharge criteria are achieved.",
"           <br>",
"            &dagger; Some experts recommend a CBC with differential and platelets at age 6 to 12 hours.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: Revised guidelines from CDC, 2010. MMWR 2010; 59 (No. RR-10):22.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_3_5183=[""].join("\n");
var outline_f5_3_5183=null;
